ideal
respiratorypulmonari
complic
observ
hsct
must
evalu
follow
predetermin
institut
protocol
lucena
et
al
includ
noninvas
test
blood
sampl
cultur
antigen
determin
sputum
cultur
nasopharyng
swab
test
cmv
respiratori
syncyti
viru
rsv
legionella
pneumocysti
jirovecii
pj
parainfluenza
viru
piv
adenoviru
adv
well
urinari
antigen
test
chest
xray
neg
empir
treatment
variabl
behavior
center
start
empir
treatment
bal
mani
other
start
treatment
bal
respons
maximum
day
galactomannan
gm
highresolut
chestcomput
tomographi
hrct
despit
includ
classif
pulmonari
complic
hsct
pulmonari
edema
pe
consequ
fluid
overload
fo
extrem
frequent
et
al
character
develop
around
day
hsct
fever
nonproduct
cough
dyspnea
tachypnea
hypoxemia
rale
diffus
alveolar
interstiti
infiltr
xray
ct
scan
follow
must
present
accept
ip
diagnosi
pathophysiolog
ip
complex
data
gener
use
experiment
model
support
ip
process
lung
suscept
two
distinct
interrel
pathway
immunemedi
injuri
tcell
axi
inflammatori
cytokin
axi
distinct
relat
pathway
inflamm
culmin
recruit
immun
cell
lung
lead
tissu
damag
dysfunct
cook
yanik
incid
strict
methodolog
requir
establish
ip
diagnosi
increas
use
ric
reduc
incid
observ
year
ago
time
ip
call
idiopath
pneumonia
reduct
run
parallel
improv
diagnost
methodolog
detect
infecti
pathogen
howev
frequent
absenc
respons
specif
treatment
detect
pathogen
suggest
true
incid
ip
may
underestim
nowaday
allohsct
mac
ric
time
within
first
day
bmt
usual
observ
day
year
ago
around
day
late
ip
observ
except
thompson
et
al
risk
factor
cook
yanik
older
age
karnofski
index
higher
interv
diagnosishsct
mac
tbi
gy
hla
dispar
gvhd
prophylaxi
mtx
acut
gvhdpreviou
viral
infect
malign
leukemia
support
measur
supplement
therapi
mechan
ventil
invas
highflow
nasal
cpap
empir
broadspectrum
antimicrobi
strict
control
fluid
balancehemofiltr
specif
treatment
mention
lung
injuri
ip
occur
two
pathway
tnfalfalp
depend
depend
cook
yanik
consequ
treatment
option
focus
direct
methylpdn
mgkgd
clear
respons
consid
soon
possibl
etanercept
mgkg
twice
weekli
maximum
dose
system
steroid
mg
kgd
random
studi
etanercept
steroid
vs
steroid
placebo
termin
prematur
due
slow
accrual
limit
number
patient
examin
differ
respons
rate
day
result
necessarili
impli
agent
effect
lack
evid
impli
lack
effect
yanik
et
al
phase
ii
trial
children
cr
rate
surviv
combin
also
shown
effect
except
case
late
ip
cr
surviv
among
respond
thompson
et
al
diffus
alveolar
hemorrhag
dah
relev
caus
acut
respiratori
failur
occur
recipi
similar
incid
autoand
allohsct
recipi
afessa
et
al
dah
probabl
consequ
damag
alveolar
capillari
basement
membran
see
chap
difficult
differenti
true
dah
alveolar
hemorrhag
associ
infect
majhail
et
al
usual
observ
within
first
month
hsct
median
day
often
preengraft
phase
howev
later
onset
encount
case
clinic
manifest
ip
hemoptysi
except
diagnosi
base
bal
criteria
ip
plu
differenti
characterist
progress
bloodier
return
bal
fluid
aliquot
least
three
segment
bronchi
indic
presenc
blood
alveoli
hemosiderinladen
macrophag
although
absenc
exclud
diagnosi
take
h
appear
note
dah
infecti
noninfecti
etiolog
majhail
et
al
risk
factor
higher
incid
tbi
highdos
cy
similar
incid
among
mac
ric
correl
platelet
count
differenti
diagnosi
classic
ip
difficult
mean
bal
ip
usual
appear
engraft
predomin
allohsct
respond
steroid
progress
fibrosi
case
dah
note
noninfecti
dah
fall
diagnost
umbrella
ip
panoskaltsismortari
et
al
perd
almost
imposs
except
lba
progress
bloodier
pulmonari
hemorrhag
fob
blood
seen
dah
dah
associ
infect
imposs
without
detect
pathogen
majhail
et
al
treatment
although
systemat
treat
high
dose
methylpdn
mg
day
follow
taper
dosag
week
aminocapro
acid
aca
overal
respons
treatment
disappoint
rathi
et
al
recent
studi
seem
show
best
treatment
use
low
steroid
dose
mgd
aca
rathi
et
al
factor
viia
addit
appear
improv
result
obtain
pdn
elinoff
et
al
tri
avoid
mechan
ventil
mean
cpap
prognosi
poor
overal
mortal
high
day
rathi
et
al
less
patient
die
direct
consequ
dah
frequent
evolut
mof
increas
mortal
auto
allohsct
afessa
et
al
dah
appear
earli
allohsct
earli
vs
late
autohsct
better
prognosi
afessa
et
al
majhail
et
al
cgvhd
specif
involv
lung
cook
et
al
cours
may
aggrav
respiratori
infect
viral
infect
gastroesophag
reflux
time
incid
averag
start
period
month
incid
year
longest
seri
arora
et
al
prospect
studi
bergeron
et
al
clinic
manifest
variabl
clinic
cours
usual
insidi
onset
progress
deterior
sometim
present
acut
fulmin
cours
progress
breathless
nonproduct
cough
wheez
although
asymptomat
case
detect
pft
necessari
carri
pft
everi
first
year
hsct
earli
detect
bo
chronic
gvhd
locat
continu
addit
lateonset
ip
mention
except
complic
thromboembol
pneumomediastinum
two
form
chronic
pulmonari
dysfunct
commonli
observ
patient
surviv
day
allohsct
one
obstruct
lung
diseas
bronchiol
obliteran
syndrom
bo
restrict
lung
diseas
cryptogenet
organ
pneumonia
cop
recent
prospect
studi
show
among
patient
includ
day
cumul
incid
lonipc
bo
year
among
allohsct
recipi
bergeron
et
al
anoth
studi
show
impact
complic
surviv
vs
wo
lonipc
nishio
et
al
pathogenesi
time
incid
clinic
manifest
diagnosi
radiolog
bo
shown
tabl
treatment
prognosi
bo
includ
tabl
formerli
call
boop
bronchiol
obliteran
organiz
pneumonia
cop
lonipc
associ
restrict
pulmonari
dysfunct
reportedli
incid
cop
among
hsct
recipi
increas
due
use
transbronchi
biopsi
diagnost
tool
greatest
diagnost
challeng
differenti
cop
bo
see
tabl
yoshihara
et
al
cook
et
al
chien
et
al
uhlv
et
al
clinic
manifest
may
asymptomat
detect
pft
absenc
activ
infect
demonstr
bal
chronic
gvhd
locat
b
obstruct
alter
air
entrap
nv
decreas
ratio
ratio
residu
volum
nonsignific
bronchodil
test
decreas
dlco
compat
radiolog
see
definit
histolog
confirm
thoracotomi
vat
transbronchi
biopsi
c
radiolog
chest
xray
normal
sign
hyperinfl
ct
scan
radiolog
pattern
constrict
bronchiol
aerial
entrap
attenu
mosaic
bronchiectasi
bronchial
wall
thicken
characterist
air
trap
exhal
dlco
transfer
capac
co
maximum
expiratori
volum
first
second
fvc
forc
vital
capac
vat
videoassist
thoracoscop
surgeri
expert
consid
decreas
basal
hsct
make
suspect
bo
diagnosi
b
lung
organ
cgvhd
biopsi
need
confirm
diagnosi
nih
criteria
c
rare
transbronchi
biopsi
use
low
sensit
low
predict
valu
establish
diagnosi
emin
clinic
histolog
avail
term
bronchiol
obliteran
use
avail
process
refer
bo
antiinfecti
prophylaxi
hypogammaglobulinemia
ivig
treatment
gastroesophag
reflux
respiratori
physiotherapi
specif
treatment
prednison
mgkgday
transient
unsatisfactori
respons
case
addit
csa
azathioprin
atg
photopheresi
advantag
budesonideinh
formoterol
shown
transient
effect
patient
bergeron
et
al
etanerceptinfliximab
effect
case
yanik
et
al
fam
combin
therapi
effect
diseas
stabil
fluticason
inhal
mcg
h
adult
mcg
children
azithromycin
mgd
adult
mgkgd
children
b
montelukast
mg
oral
night
adult
mg
children
two
week
fam
increas
start
pdn
mgkgd
decreas
mgkgd
week
william
et
al
bo
control
sever
residu
respiratori
insuffici
lung
transplant
may
consid
year
cheng
et
al
prognosi
trm
high
year
hsct
almost
alway
get
associ
progress
respiratori
failur
opportunist
infect
srv
around
year
fluticason
theoret
decreas
inflammatori
pulmonari
compon
azithromycin
reduc
level
neutrophilia
montelukast
antagonist
leukotrien
receptor
bronchodil
b
howev
allozithro
random
trial
shown
earli
administr
azithromycin
result
wors
airflow
declinefre
surviv
placebo
valu
find
limit
earli
termin
trial
bergeron
et
al
lung
injuri
occur
frequent
follow
hsct
significantli
contribut
morbid
mortal
immedi
post
transplant
period
month
year
follow
observ
recipi
noninfecti
lung
injuri
follow
hsct
may
mediat
either
immun
nonimmun
mechan
could
repres
noninfecti
mortal
allohsct
relev
noninfecti
earli
pulmonari
complic
pulmonari
edema
fluid
overflow
idiopath
pneumonia
syndrom
diffus
alveolar
hemorrhag
vascular
endotheli
syndrom
relev
lateonset
noninfecti
pulmonari
complic
bronchiol
obliteran
cryptogenet
organ
pneumonia
specif
diagnost
criteria
manag
treatment
prognosi
